Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice

Infection and Immunity

Volumn 70, Issue 4, 2002, Pages 2100-2107

  Moreira, Andre L ^a   Tsenova, Liana ^a   Aman, Melles Haile ^a   Bekker, Linda Gail ^a   Freeman, Sherry ^a   Mangaliso, Bande ^a   Schröder, Ulf ^a   Jagirdar, Jaishree ^a   Rom, William N ^a   Tovey, Michael G ^a   Freedman, Victoria H ^a   Kaplan, Gilla ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; MYCOBACTERIUM ANTIGEN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BCG VACCINATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; LUNG GRANULOMA; LYMPHOCYTE PROLIFERATION; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUBERCULOSIS; VACCINATION;

ANIMALS; ANTIGENS, BACTERIAL; BCG VACCINE; FEMALE; INTERLEUKIN-6; LUNG; LYMPHOCYTE ACTIVATION; MICE; MYCOBACTERIUM; RNA, MESSENGER; T-LYMPHOCYTES; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 0036128967     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.4.2100-2107.2002     Document Type: Article

References (25)

1. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis
2. Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent
3. Selective increase in plasma TNF-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis
4. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis
5. Oromucosal interferon therapy: Pharmacokinetics and pharmacodynamics
6. Vaccines, genes and trials
7. Variation in protection by BCG: Implications of and for heterologous immunity
8. Clinical considerations in designing trials of vaccines for tuberculosis
9. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine
10. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: A comparison of two treatment regimes and placebo
11. Randomised controlled trial of single BCG, repeated BCG, or combined BCG, and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi
12. Weitere. Mitteilungen uber ein heilmittel gegen tuberkulose
13. Perforin, a cytotoxic molecule which mediates cell necrosis, is not required for early control of mycobacterial infection in mice
14. Therapy of tuberculosis in mice by DNA vaccination
15. Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis
16. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines
17. Demonstration of acquired resistance in Bcgr inbred mouse stains infected with a low dose of BCG montreal
18. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination
19. Vaccination against tuberculosis by DNA injection
20. Aerosol infection of mice with mycobacteria using a nose-only exposure device
21. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode
22. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens
23. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages